Section Arrow
Quote
DMRA.NASDAQ
- Damora Therapeutics Inc.
Quotes are at least 15-min delayed:2026/03/10 16:12 EDT
After Hours
Last
 25.51
0 (0.00%)
Bid
10.31
Ask
30.38
High 25.51 
Low 25.51 
Volume 42 
Regular Hours (Closed)
Last
 25.51
-3.17 (-11.05%)
Day High 
29.22 
Prev. Close
28.68 
1-M High
-- 
Volume 
216.57K 
Bid
10.31
Ask
30.38
Day Low
25 
Open
27.99 
1-M Low
-- 
Market Cap 
1.73B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High -- 
52-W Low -- 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-12.11/-57.51
Enterprise Value
1.73B
Balance Sheet
Book Value Per Share
0.11
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
LGVNLongeveron0.891+0.3611+68.14%-- 
After Hours 0.8642 -0.0268 -3.01%
BRTXBioRestorative Therapies0.2814+0.04675+19.92%-- 
After Hours 0.2745 -- --
ACXPAcurx Pharmaceuticals2.9+0.945+48.34%-- 
After Hours 2.94 +0.04 +1.38%
PLYXPolaryx Therapeutics Inc5.97+2.44+69.12%-- 
After Hours 5.8712 -- --
IBRXImmunityBio8.01-0.44-5.21%-- 
After Hours 7.95 -0.06 -0.75%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.